Commentary

Video

Dr Mayer on Niraparib Plus Dostarlimab in ER+ BRCA/PALB2-Mutated Breast Cancer

Author(s):

Erica L. Mayer, MD, MPH

Fact checked by:

Ashling Wahner ,Chris Ryan
Conference|San Antonio Breast Cancer Symposium

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School, discusses findings with the use of neoadjuvant niraparib (Zejula) plus dostarlimab-gxly (Jemperli) from the estrogen receptor (ER)–positive, HER2-negative, BRCA/PALB2-mutated breast cancer cohort of the phase 2 TBCRC 056 trial (NCT04584255).

Related Videos
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Related Content
Daniel DeAngelo, MD, PhD
January 9th 2025

Blinatumomab Becomes Standard Addition to Consolidation Chemo in B-ALL, Irrespective of MRD Status

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

Cancer | Image Credit: © Cornflakesei - stock.adobe.com
January 8th 2025

Dana-Farber Launches Center for RAS Therapeutics to Target the RAS Oncogene in Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Toni Choueiri, MD
January 8th 2025

TiNivo-2 Data Underscore Challenges With ICI Retreatment in Advanced RCC

Cancer | Image Credit: © Katsyarina – stock.adobe.com
January 6th 2025

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers